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INTRODUCTION
BK virus-associated nephropathy (BKVAN) is an impor-
tant cause of allograft loss in kidney transplant recipients
(1-3). The prevalence of BKVAN has increased from 1% to
10% in the past decade (4). Although reasons for this increase
have not been determined, it may be associated with the
introduction of more-potent immunosuppressive agents, the
increasing awareness of this disease by clinicians, and advances
in diagnostic techniques (5). Because BKVAN patients show
progressive allograft dysfunction without specific symptoms,
it is difficult to differentiate BKVAN from acute graft rejec-
tion (6). The definitive diagnosis of BKVAN requires renal
biopsy to prove viral cytopathic effects in renal tubular epithe-
lium (7). BKVAN, however, can be coincident with acute
cellular rejection, and early infiltrations frequently involve
only the medulla, which is usually not included in renal biop-
sy (8, 9). Consequently, additional diagnostic modalities are
required to diagnose BKVAN (10). Urine cytology has been
used as a noninvasive screening test, but the presence of decoy
cells containing viral inclusions is not a specific marker of
BKVAN (11). Although quantitative polymerase chain reac-
tion (PCR) of BK virus DNA (BKDNA) may be a more
sensitive and specific test (7, 12, 13), quantitative assays of
BKDNA have not been standardized, and individual labo-
ratories need to establish and validate their own cutoffs. Sev-
eral clinical laboratories in Korea have quantitatively mea-
sured BKDNA, but cutoff values for BKVAN have not been
determined yet. We have therefore utilized real-time PCR to
establish BKDNA cutoff values for the diagnosis of BKVAN. 
MATERIALS AND METHODS
Patients and specimens
All renal transplant recipients who underwent renal biop-
sy and quantitative measurement of BKDNA in both plas-
ma and urine between June 2005 and February 2007 to diag-
nose the cause of renal impairment were retrospectively en-
rolled. Patients’ medical records were reviewed for demo-
graphic findings and pathologic and clinical diagnoses. BK-
VAN was diagnosed by the presence of intranuclear viral inclu-
sion bodies in epithelial cells and the immunohistochemical
detection of SV40 antigen in renal biopsy specimens. DNA
was extracted from 200 μ L aliquots of urine and plasma using
QIAamp MinElute Virus Spin Kits (Qiagen, Valencia, CA,
U.S.A.) and eluted into 40 μ L. 
Quantitative measurement of BKDNA
As the standard, the plasmid pBKV 34-2, containing the
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Quantitation of BK Virus DNA for Diagnosis of BK Virus-Associated
Nephropathy in Renal Transplant Recipients
Quantitative measurement of BK virus DNA (Q-BKDNA) has been used for the
early diagnosis and monitoring of BK virus-associated nephropathy (BKVAN). This
study was designed to determine the BKDNA cutoff for the diagnosis of BKVAN.
Between June 2005 and February 2007, 64 renal transplant recipients taken renal
biopsies due to renal impairment submitted plasma and urine for Q-BKDNA. Eight
BKVAN patients (12.5%) had median viral loads of 6.0 log10 copies/mL in plasma
and 7.3 log10 copies/mL in urine. Among 56 non-BKVAN patients, 45 were negative
for Q-BKDNA; 4 were positive in plasma with a median viral load of 4.8 log10 copies/
mL, and 10 were positive in urine with a median viral load of 4.8 log10 copies/mL.
Receiver operating characteristic curve analysis showed that a cutoff of 4.5 log10
copies/mL in plasma and a cutoff of 5.9 log10 copies/mL in urine had a sensitivity of
100% and a specificity of 96.4%, respectively. A combined cutoffs of 4 log10 copies/
mL in plasma and 6 log10 copies/mL in urine had better performance with a sensi-
tivity of 100% and a specificity of 98.2% than each cutoff of urine or plasma. Q-
BKDNA with the combined cutoffs could reliably diagnose BKVAN in renal trans-
plant recipients.
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entire linearized genome of the BKV Dunlop strain insert-
ed into the BamHI restriction site of pBR322, obtained from
the American Type Culture Collection (ATCC 45025; Man-
assas, VA, U.S.A.), was grown in TOPO TA Cloning TOP10
cells (Invitrogen Corporation, Carlsbad, CA, U.S.A.) and
purified with QIAprep Spin Miniprep kit (Qiagen). Plasmid
concentration was measured by optical density using an Ultro-
spec 3000 spectrophotometer (Amersham Pharmacia Biotech,
Piscataway, NJ, U.S.A.) and the number of viral genome
equivalent copies was calculated using the equation: amount
of DNA (pg)/1012×6.023×1023/(660×9,363 bp) (14). A
standard curve was plotted at estimated concentrations of
0.3, 1.3, 2.3, 3.3, 5.3, and 7.3 log10 copies/μ L.
Quantitative real-time PCR assays were performed using
the LightCycler (Roche Diagnostics, Palo Alto, CA, U.S.A.),
with BKDNA measured by the hybridization probe method.
The sequences of the primers for the large T antigen gene
(GenBank accession number V01108) were 5′ -ACAGCA-
AAGCAGGCAAGG-3′ and 5′ -GGAGTCCTGGTGGA-
GTTCC-3′ , and the probe sequences were 5′ -LC Red640-
AAGCAACAGCAGATTCTCAACACTCAACA-phosphate
and 5′ -TTTTGCCATGAAGAAATGTTTGCCAGTGAT-
GA-fluorescein-3′ , all designed by TIB MOLBIOL (Berlin,
Germany). PCR amplifications were run in a reaction vol-
ume of 20 μ L containing 2 μ L of DNA sample, 10× Light-
Cycler-FastStart DNA Master Hybridization Probes (Roche
Molecular Biochemicals, Mannheim, Germany), 3 mM mag-
nesium chloride, 500 nM of each primer, and 200 nM of
each probe. The amplification protocol was consisted of an
initial denaturation at 95℃ for 10 min, followed by 45
cycles of denaturation at 95℃ for 10 sec, annealing at 57℃
for 10 sec, and extension at 72℃ for 20 sec. Postamplifica-
tion melting curve analysis was performed to distinguish
BKV-specific amplicon melted at 66℃ from nonspecific
melting.
Statistical analysis
Data were expressed as median values and ranges. Statisti-
cal significance was estimated by Student’s two-tailed t test
or Fisher’s exact test, and Mann-Whitney test, with α =0.05
(SPSS package version 12.0). Receiver operating characteris-
tic (ROC) curve analysis was used to determine the BKDNA
cutoffs for diagnosis of BKVAN; ROC curves were obtained
using a statistical package program from MedCalc (MedCalc,
Mariakerke, Belgium). 
RESULTS
Characteristics of patients
Between June 2005 and February 2007, 64 renal transplant
recipients underwent renal biopsy, along with quantitative
measurement of BKDNA (Q-BKDNA) in both plasma and
urine, to diagnose the cause of renal impairment. The charac-
teristics of the patients are listed in Table 1. 
Eight patients (12.5%) were diagnosed with BKVAN
based on pathologic findings; their median age was 40.5 yr
(range, 22-60 yr) and 6 (75.0%) were male. BKVAN was
diagnosed at 2.5-28 months post-transplantation (median,
5.8 months); 5 BKVAN patients (62.5%) were diagnosed
within 6.5 months, but the other 3 were diagnosed after
16.5 months. Renal biopsy revealed concurrent acute cellu-
lar rejection in 6 (75.0%) of these patients. The median level
of serum creatinine was 2.3 mg/dL (range, 1.9 to 3.2 mg/dL;
reference 0.7-1.4 mg/dL) (Table 1).
Fifty-six (87.5%) of the 64 patients had no pathologic evi-
dence of nephropathy. Their median age was 45.0 yr (range,
13 to 64 yr) and 37 (66.1%) were male. Renal biopsies ob-
tained at 0.3 to 176 months post-transplantation (median,
8.5 months) showed acute cellular rejection in 32 patients
(57.1%). The median level of serum creatinine was 2.4 mg/
dL (range, 1.4-12.4 mg/dL) (Table 1).
There were no significant differences between BKVAN
and non-BKVAN patients in age, sex, duration after kidney
transplantation, acute cellular rejection, and creatinine level
at renal biopsy (p>0.05 for all comparisons).
BKV viral loads
Calibration with standard DNA showed a wide linear
range, from 0.6 to 7.6 log10 copy equivalents of viral DNA,
with a sensitivity of as little as 2.2 copy equivalents. This
BKVAN
(n=8)
Non-BKVAN
(n=56)
p
value*
Age, median years (range) 40.5 (22-60) 45 (13-64) 0.43
Male sex (%) 6 (75.0) 37 (66.1) 1.00
Months after transplantation,  5.8 (2.5-28) 8.5 (0.3-176) 0.84
median (range)
Serum creatinine (mg/dL),  2.3 (1.9-3.2) 2.4 (1.4-12.4) 0.22
median (range)
Pathologic findings
Acute cellular rejection 4 24 0.72
Acute humoral rejection 0 2 -
Acute cellular rejection,  0 3 -
acute humoral rejection
Acute tubular injury 0 6 -
Acute cellular rejection,  2 5 0.21
recurred IgA nephropathy
Recurred IgA nephropathy 1 4 0.50
Chronic allograft nephropathy 0 5 -
Others 0 5 -
Normal 0 2 -
Table 1. Characteristics of the 8 transplant recipients with doc-
umented BK virus-associated nephropathy (BKVAN) and the
56 transplant recipients without BKVAN (non-BKVAN)
*, Between BKVAN and non-BKVAN patients.816 H. Sung, B.H. Choi, Y.J. Pyo, et al.
corresponds to a linear range of 2.6 to 9.6 log10 copies/mL
with a detection limit of 2.3 log10 copies/mL.
The overall prevalence of BKV DNAemia and DNAuria
were 18.8% (12/64) and 28.1% (18/64), respectively. The
median BKV loads in plasma and urine from BKVAN pati-
ents were 6.0 log10 copies/mL (range, 5.0-6.9 log10 copies/mL)
and 7.3 log10 copies/mL (6.3-9.3 log10 copies/mL), respective-
ly (Fig. 1). Forty-five (80.4%) of the 56 non-BKVAN patients
were negative for BKDNA in both urine and plasma. Four
(7.1%) non-BKVAN patients were positive for BKDNA in
plasma, with a median viral load of 4.8 log10 copies/mL (range,
3.9-5.6 log10 copies/mL), whereas 10 (17.9%) non-BKVAN
patients were positive for BKDNA in urine, with a median
viral load of 4.8 log10 copies/mL (range, 3.6-7.8 log10 copies/
mL) (Fig. 1). BKV DNA loads both in plasma and urine were
higher in the BKVAN patients than in the non-BKVAN
patients (p<0.001). All BKVAN patients were positive for
BKDNA in both plasma and urine. In contrast, only 3 (5.4%)
non-BKVAN patients showed both BKV DNAemia and
DNAuria (Table 2).
ROC curve analysis showed that a cutoff of 4.5 log10 copies/
mL BKDNA in plasma and a cutoff of 5.9 log10 copies/mL in
urine had a sensitivity of 100% and a specificity of 96.4%,
respectively (Fig. 2). Using each cutoff, 2 non-BKVAN
patients were misclassified as having BKVAN. As a result, a
total of 3 patients were falsely positive by at least one of the
two criteria: one patient with a plasma viral load of 5.6 log10
copies/mL and a urine viral load of 6.5 log10 copies/mL; one
patient with a plasma viral load of 5.2 log10 copies/mL, and
one patient with a urine viral load of 7.8 log10 copies/mL.
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Fig. 1. Distribution of BK virus DNA loads in BK virus-associated
nephropathy (BKVAN) and non-BKVAN patients. Data are exp-
ressed as log10 viral copies/mL. Dashed lines indicate the sug-
gested viral load cutoffs for diagnosis of BKVAN.
Fig. 2. Receiver operating characteristics curve for diagnosis of BKVAN and (A) plasma BKV DNA levels, and (B) urine BKV DNA levels,
respectively. A cutoff of 4.5 log10 copies/mL in plasma and a cutoff of 5.9 log10 copies/mL in urine showed the best performance, respec-
tively.
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B
No. (%) of patients
BKVAN (%) Non-BKVAN (%)
BKDNA
Plasma +/urine + 8 (100) 3 (5.4)
Plasma +/urine - 0 (0) 1 (1.8)
Plasma -/urine + 0 (0) 7 (12.5)
Plasma -/urine - 0 (0) 45 (80.4)
Total 8 (100) 56 (100)
Table 2. The results of quantitation of BKDNA in 8 BKVAN pati-
ents and 56 non-BKVAN patients
BKDNA, BK virus DNA; BKVAN, BK virus-associated nephropathy.Quantitation of BK Virus DNA 817
With the combined cutoffs of 4 log10 copies/mL in plasma
and 6 log10 copies/mL in urine, two of three false positive
patients were excluded, and the specificity was 98.2%.
DISCUSSION
We found that the overall prevalence of BKV DNAemia,
DNAuria, and BKVAN were 18.8%, 28.1%, and 12.5%,
respectively. The prevalence of BKV DNAemia, DNAuria,
and BKVAN have been reported as 5-29%, 10-57%, and
1-10%, respectively (2, 4, 15-19). These wide ranges may
be due to differences in post-transplantation period when
samples were obtained, in immunosuppressive regimens,
and in the percentages of seronegative recipients (17). We
found that the prevalence of BKVAN was higher than pre-
vious studies (2, 4, 15-19). This was not surprising, since
the patients in this study were confined to those with renal
impairment, whereas most previous studies were based on
prospective monitoring of renal transplant recipients. While
most studies have found that the prevalence of BKV DNAu-
ria was twice as high as the prevalence of DNAemia (2, 4,
15-19), we found that this ratio was only 1.5:1. Because we
did not include an internal control in our assays, the possi-
bility of residual PCR inhibitors in DNA extracts from urine
specimens could not be ruled out. Urine specimens tend to
have more residual inhibitors (20). To estimate the effects of
these inhibitory substances on cutoff values and positivity
rates, internal controls should be included in real-time PCR-
based assays. 
We found that 5 of the 8 BKVAN cases were diagnosed
within 6.5 months after transplantation, whereas the other
3 were diagnosed from 16.5 months to 28 months. BKVAN
has been reported to occur from 2 to 60 months post-trans-
plantation (5). One early report described a bimodal distribu-
tion of BKVAN, with 50% occurring 4-8 weeks after trans-
plantation and the remainder developing months to years
later (21). More recently, the majority of BKVAN cases were
found to occur within the first year after transplantation,
with approximately 25% diagnosed later (3, 22). Although
the number of included patients was small, our results are
consistent with this bimodal distribution. Therefore, regu-
lar monitoring of BKDNA for more than 2 yr after trans-
plantation is required for the timely diagnosis of BKVAN.
It has been recommended that renal transplant recipients be
monitored for BKDNA at least every 3 months during the
first 2 yr post-transplantation and thereafter annually until
5 yr after transplantation (23).
We found that a cutoff of 4.5 log10 copies/mL BKDNA in
plasma and a cutoff of 5.9 log10 copies/mL in urine had a sen-
sitivity of 100% and a specificity of 96.4% in identifying
patients with BKVAN. Previous studies have found that
plasma BKDNA >3.7 log10 copies/mL or >4 log10 copies/
mL and/or urine BKDNA of >7 log10 copies/mL can be used
to diagnose BKVAN (1, 3, 22, 24). Compared to those cri-
teria, our urine cutoff value was 1 log10 copies/mL lower, while
our plasma cutoff value was similar. Because there has been
no external quality control survey program for BKV quan-
tification to date, it is difficult to determine the accuracy of
this assay (7). Our finding, the lower cutoff level for urine,
may be associated with partial inhibition of quantitative mea-
surement of BKDNA in urine. We found that the use of a
combined cutoffs of 4 log10 copies/mL in plasma and 6 log10
copies/mL in urine improved the specificity up to 98.2%.
Since renal biopsy is highly invasive, the diagnostic speci-
ficity of Q-BKDNA is important. Thus, simultaneous mea-
surement of BKDNA in both plasma and urine may be used
to monitor renal transplant recipients for BKVAN. 
In conclusion, BKVAN was significant cause of renal im-
pairment in renal transplant recipients. Q-BKDNA could
reliably diagnose BKVAN in renal transplant recipients using
a combined cutoffs of 4 log10 copies/mL in plasma and 6 log10
copies/mL in urine. 
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